loading
Overview
Strategic Report
Governance
Financial Statements
Company Information
Annual Report and Accounts for the year ended 30 June 2019
Download the PDF of the Annual Report 2019
Dechra is a global specialist veterinary pharmaceuticals and related products business.
Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide.
It is our mission to develop products sustainably to improve the welfare of animals globally.
68
Countries in which our products are sold via a distributor
25
Countries in which our sales and marketing teams are based
7
Manufacturing sites
Read more on Growing Our Geographical Footprint
We continued to execute our strategy in relation to our pipeline delivery, portfolio focus, geographic expansion and acquisition.
Tony Rice
Non-Executive Chairman
Read more on the Chairman's View
Watch video
Read more
Our existing business performed strongly this year and was further enhanced by the realisation of significant revenue synergies. The Group’s balance sheet is strong and we continue to invest both organically and through acquisitions to deliver shareholder value.
£481.8m
2018: £407.1m
AER: +18.3% CER: +17.5%
£127.4m
2018: £99.2m
AER: +28.4% CER: +27.3%
£90.01p
2018: 76.45p
AER: +17.7% CER: +16.6%
£31.60p
2018: 25.50p
AER: +23.9% CER: +23.9%
£39.0m
2018: £34.1m
AER: +14.4% CER: +13.5%
£30.07p
2018: 37.04p
AER: (18.8%) CER: (19.6%)
Recent acquisitions performing ahead of expectations.
CAP outperformance in all key markets.
FAP growth continuing.
Numerous product registrations achieved, and new development opportunities secured.
Read more on Financial Performance
Since 2013, our priorities for each Strategic Growth Driver and Enabler have been clearly defined and communicated and are outlined on Our Achievements and Progress. In this online Annual Report we describe the progress we have made towards achieving our strategic objectives.
We are implementing a strong technology platform to enable us to operate efficiently. We also offer CPD training via our e-learning system to veterinarians and veterinary nurses.
Our people strategy underpins everything we do in the business. We have a well defined plan to build talent, develop people and strengthen the Dechra culture.
Manufacturing is a key competency of the Group; the prime objective is to deliver safe, efficacious, costeffective, quality products. Our products are distributed to wholesalers and distributors through two major logistics sites.
Deliver our pipeline on time, at the right costs and with the expected returns. Refill the pipeline so that we get a constant flow of new products in future years.
Maximise our revenue by increasing market penetration, focusing on targeted therapeutic sectors within CAP, Equine, FAP and Nutrition.
Leverage our product portfolio into new geographic regions through distribution partners, in-country presence and new country product registrations.
Expand our geographical footprint and/or enhance our product portfolio through acquisition.
Read more on Delivering our Strategy
2013
1,327
2019
5,407
40
13
3
1,287
1,753
A key strategic priority for the Group is the delivery and strength of the pipeline. We currently have 56 projects in the product development process.
1
Feasiblity
12
2
Research
16
Development
19
4
Registration
9
Read more on our Product Development
Strategy in Action
Pipeline Delivery
Delivering our pipeline through licensing opportunities
Read more on our Pipeline Delivery
Portfolio Focus
Dechra Dog & Cat App
Read more on our Portfolio Focus
Geographical Expansion
Acquisition
Laboratorios Vencofarma do Brasil Ltda, Brazil
Read more on our Geographical Expansion and Acquisition